Long-term surgical outcomes of Non alcoholic fatty liver disease associated hepatocellular carcinoma

被引:1
作者
D'Silva, Mizelle [1 ]
Cho, Jai Young [1 ]
Han, Ho-Seong [1 ]
Yoon, Yoo-Seok [1 ]
Lee, Hae Won [1 ]
Lee, Jun Suh [1 ]
Lee, Boram [1 ]
Kim, Moonhwan [1 ]
机构
[1] Seoul Natl Univ, Seoul Natl Univ Coll Med, Dept Surg, Bundang Hosp, Gumi Ro 173, Seongnam Si 13620, Gyeonggi Do, South Korea
来源
SURGICAL ONCOLOGY-OXFORD | 2022年 / 41卷
关键词
Anatomical liver resection; Non-alcoholic steatohepatitis; Systemic disease-free survival; Cirrhosis; Cryptogenic; PATHOGENESIS; IMPACT;
D O I
10.1016/j.suronc.2022.101730
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The global burden of non-alcoholic fatty liver disease (NAFLD) and NAFLD-associated hepatocellular carcinoma (HCC) is steadily rising. We pursued to investigate the results after liver resection for NAFLD-HCC versus hepatitis B virus (HBV)-HCC exploiting Kaplan Meier method, log-rank test and uni/multivariate analysis with the logistic regression models".Methods: Patients who underwent liver resection for HCC between January 2004 and December 2018 were included. The outcomes of NAFLD-associated HCC were analyzed.Results: The prevalence of NAFLD-associated HCC was 8.4%. A significant number of NAFLD patients had no cirrhosis (21 patients; 38.8%). Although NAFLD patients had a significantly better 5-year survival (P = 0.033), NAFLD was not significantly associated with overall survival in multivariate analysis (P = 0.287). However, survival after 5 years declined in NAFLD patients and was similar to HBV. NAFLD was protective against systemic recurrence compared with HBV (P = 0.018), and this was confirmed in multivariate analysis (P = 0.044). Fiveyear systemic recurrence (P = 0.044) was significantly lower in NAFLD patients and decreased with time from surgery. Multivariate analysis revealed that anatomical liver resection was independently associated with decreased recurrence in NAFLD patients (HR = 0.337; P = 0.033).Conclusion: Overall survival is similar between NAFLD-associated HCC and HBV-associated HCC. Despite there being no significant difference between liver function tests, type of surgery performed, liver cirrhosis, size of tumor, number of tumors, pathological factors like satellite nodules and Edmonson Steiner staging, NAFLDassociated HCC shows lower systemic recurrence compared to HBV-associated HCC.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease
    Tian, Yuan
    Wong, Vincent Wai-Sun
    Chan, Henry Lik-Yuen
    Cheng, Alfred Sze-Lok
    SEMINARS IN CANCER BIOLOGY, 2013, 23 (06) : 471 - 482
  • [22] Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma
    Anastasopoulos, Nikolaos-Andreas T.
    Lianos, Georgios D.
    Tatsi, Vera
    Karampa, Anastasia
    Goussia, Anna
    Glantzounis, Georgios K.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 14 (11) : 1025 - 1033
  • [23] Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma
    Kawamura, Yusuke
    Arase, Yasuji
    Ikeda, Kenji
    Seko, Yuya
    Imai, Norihiro
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Saitoh, Satoshi
    Sezaki, Hitomi
    Akuta, Norio
    Suzuki, Fumitaka
    Suzuki, Yoshiyuki
    Ohmoto, Yuki
    Amakawa, Kazuhisa
    Tsuji, Hiroshi
    Kumada, Hiromitsu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (02) : 253 - 261
  • [24] Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease
    Shili-Masmoudi, Sarah
    Wong, Grace Lai-Hung
    Hiriart, Jean-Baptiste
    Liu, Ken
    Chermak, Faiza
    Shu, Sally She-Ting
    Foucher, Juliette
    Tse, Yee-Kit
    Bernard, Pierre-Henri
    Yip, Terry Cheuk-Fung
    Merrouche, Wassil
    Chan, Henry Lik-Yuen
    Wong, Vincent Wai-Sun
    de Ledinghen, Victor
    LIVER INTERNATIONAL, 2020, 40 (03) : 581 - 589
  • [25] Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover
    Simon, Jorge
    Ouro, Alberto
    Ala-Ibanibo, Lolia
    Presa, Natalia
    Cardoso Delgado, Teresa
    Luz Martinez-Chantar, Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (01)
  • [26] Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention
    Baffy, Gyorgy
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2013, 1 (02) : 131 - 137
  • [27] Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at MRI
    Thompson, Scott M.
    Garg, Ishan
    Ehman, Eric C.
    Sheedy, Shannon P.
    Bookwalter, Candice A.
    Carter, Rickey E.
    Roberts, Lewis R.
    Venkatesh, Sudhakar K.
    BRITISH JOURNAL OF RADIOLOGY, 2018, 91 (1092)
  • [28] Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis:Paving the way to hepatocellular carcinoma
    Matthias Ocker
    World Journal of Gastroenterology, 2020, (03) : 279 - 290
  • [29] Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma
    Ocker, Matthias
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (03) : 279 - 290
  • [30] Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice
    Yokohama, Keisuke
    Fukunishi, Shinya
    Ii, Masaaki
    Nakamura, Ken
    Ohama, Hideko
    Tsuchimoto, Yusuke
    Asai, Akira
    Tsuda, Yasuhiro
    Higuchi, Kazuhide
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2016, 38 (05) : 1499 - 1506